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Objectives: To determine the effect of cloned inhibitor-resistant TEM b-lactamases (IRTs) on the
susceptibility of Haemophilus influenzae to amoxicillin/clavulanate.
Methods: IRT-2, -4 and -5 genes with various promoters were cloned into control strains of H. influen-
zae and the amoxicillin/clavulanate MICs were measured using Etests.
Results: IRT enzymes were able to raise the amoxicillin/clavulanate MICs to between 0.38/0.19 and 4.0/
2.0 mg/L depending on the IRT and promoter genotype, compared with MICs of 0.19/0.09 to 0.5/
0.25 mg/L for the corresponding strains with TEM-1. Strains with an IRT and altered penicillin-binding
proteins had amoxicillin/clavulanate MICs as high as 8.0/4.0 mg/L.
Conclusions: Cloned IRT enzymes in H. influenzae raise the amoxicillin/clavulanate MICs to an extent
comparable to naturally occurring strains with decreased amoxicillin/clavulanate susceptibility.
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Introduction
The most common mechanism of ampicillin resistance in
Haemophilus influenzae is via production of TEM-1 b-lactamase
with a recent global survey reporting a prevalence of 17%.1 One
strategy used to overcome this resistance is to use amoxicillin in
combination with the b-lactamase inhibitor clavulanate, and this
combination is widely prescribed to treat a range of respiratory
tract infections caused by b-lactamase-producing strains of
H. influenzae.2 Despite the prevalence of TEM-1 b-lactamase in
H. influenzae and the widespread use of amoxicillin/clavulanate, it
has been surprising that inhibitor-resistant TEM b-lactamases
(IRTs) and associated amoxicillin/clavulanate resistance has not
been reported in H. influenzae as it has in Enterobacteriaceae.3,4
This is especially so given that amoxicillin/clavulanate resis-
tance has emerged in b-lactamase-negative ampicillin-resistant
(BLNAR) and b-lactamase-positive amoxicillin/clavulanate-
resistant (BLPACR) strains of H. influenzae as a result of altered
penicillin-binding proteins (PBPs).5,6 It has been suggested that the
failure of IRTs to emerge in H. influenzae might be associated with
the high intrinsic activity of penicillins against the organism and
relatively small amounts of b-lactamase usually produced,3,4 such
that a level of resistance sufficient to allow for selection of mutants
during therapy might not be produced.
In order to determine the effect that IRTs might have on the
susceptibility to ampicillin and amoxicillin/clavulanate, a range
of IRTs were artificially introduced into control strains of
H. influenzae.
Methods
Construction of blaTEM-1 and blaIRT library
Strains of TEM-1 b-lactamase-positive H. influenzae, previously
characterized with regard to promoter genotype,7,8 were used as
PCR templates to clone blaTEM-1 with Pa/Pb, Pdel or Prpt promoters
onto the shuttle vector pLS88 and into Escherichia coli XL1-Blue
cells (Stratagene) as previously described.9
Plasmids were extracted from these clones and used as template
for site-directed mutagenesis using the QuikChange Site Directed
Mutagenesis Kit (Stratagene) and primers listed in Table 1 to gener-
ate blaIRT-2 and blaIRT-5 coding for IRT-2 (TEM-30) and IRT-5
(TEM-33) in E. coli XL1-Blue cells. Plasmid containing blaIRT-5
was extracted and subjected to another round of site-directed muta-
genesis to generate blaIRT-4 coding for IRT-4 (TEM-35).
Finally, all constructed plasmids (pLS88 with blaTEM-1 and
blaIRT-2, -4 and -5) were used to transform H. influenzae Rd. Plasmids
containing blaTEM-1, blaIRT-4 and blaIRT-5 in association with the
Pdel promoter were also used to transform H. influenzae Rd that
had previously been transformed with ftsI gene PCR products
from a BLNAR strain. All transformations were performed by
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electroporation as described by Ubukata et al.,5 and transformants
were selected on chocolate agar supplemented with 30 mg/L
kanamycin.
Validation of constructs
The presence of the respective blaTEM-1 and blaIRT genes in the
E. coli strains was confirmed by appropriate MICs of ampicillin and
amoxicillin/clavulanate and by bla gene sequencing. b-Lactamase
production in the H. influenzae transformants was confirmed by
nitrocefin hydrolysis (Oxoid, Australia).
Susceptibility tests
MICs of ampicillin, amoxicillin/clavulanate and cefotaxime (for
Haemophilus only) were determined using Etest strips according to
the manufacturer’s instructions (Australian Laboratory Services,
Melbourne). H. influenzae ATCC 49247 and ATCC 49766 were
used as quality control strains.
Results and discussion
The enzymes IRT-2, -4 and -5 were chosen for this study
because they are representative of enzymes with substitutions at
positions 69, 244 and 276 identified by computerized modelling
as positions that are associated with inhibitor resistance via
different molecular interactions.3 Substitutions at these positions
are also those most frequently reported in clinically derived
IRTs.10 Promoters Pa/Pb, Pdel and Prpt were chosen because
they have been identified as the most common promoters in
blaTEM-1 genes in H. influenzae.
7,8
In E. coli XL-1, the ampicillin MICs for the strains expres-
sing any of the cloned blaTEM-1 and blaIRT-2, -4 and -5 constructs
were .256 mg/L, and the amoxicillin/clavulanate (2:1 ratio)
MICs ranged from 8/4 to 32/16 mg/L for strains expressing
blaTEM-1 and 24/12 to 128/64 mg/L for blaIRT-2, -4 and -5. These
MIC data are consistent with similar naturally occurring
strains,4,11 and, in conjunction with sequence data confirming
the presence of appropriate promoters and IRT-related substi-
tutions, validate the constructs as representative of naturally
occurring resistance genes.
In H. influenzae, the amoxicillin/clavulanate MICs for strains
expressing various cloned blaIRTs were between 2- and 10-fold
higher than for strains expressing blaTEM-1 from the same pro-
moters (Table 2). All the strains expressing cloned blaIRTs had
amoxicillin/clavulanate MICs between 2- and 5-fold higher
when associated with either the strong Pdel or Prpt promoters
compared with the relatively weaker Pa/Pb promoters. This is
consistent with what is seen in naturally occurring IRT-
producing strains of E. coli, where the relatively stronger Pa/Pb
or P4 promoters occur more frequently than the weaker P3 pro-
moter.12 Stronger promoters are probably selected for because of
the decreased catalytic efficiency reported for many IRT
enzymes,4 where additional enzyme production is not only
necessary to produce significant amoxicillin/clavulanate resist-
ance but also to compensate for a relative loss of activity against
ampicillin. In the H. influenzae strains in this study, this loss of
catalytic efficiency is manifested as lower ampicillin MICs for
IRT-2- compared with TEM-1-producing strains, which is con-
sistent with the lower catalytic efficiency of IRT-2 compared
with IRT-4 and IRT-5 and TEM-1.4 Such decreases are not
observed in the E. coli constructs in this study, or in naturally
occurring IRT-positive E. coli strains because the ampicillin
MICs are usually above the highest concentrations measured.
The cefotaxime MICs for all H. influenzae clones were
between 0.008 and 0.016 mg/L with no evidence of decreased
susceptibility associated with production of IRT-2, -4 or -5
enzymes compared with TEM-1.
When IRT enzymes were expressed in BLNAR strains of
H. influenzae, the amoxicillin/clavulanate MICs were 2–5-fold
higher than those for otherwise identical non-BLNAR strains.
Table 2. MICs (mg/L) for H. influenzae with various bla genes
Host strain bla gene Promoter Ampicillin Amoxicillin/clavulanate
Rd TEM-1 Pa/Pb 16 0.19/0.09
Pdel 128 0.5/0.25
Prpt 64 0.38/0.19
IRT-2 Pa/Pb 2 0.38/0.19
Pdel 32 2.0/1.0
Prpt 32 2.0/1.0
IRT-4 Pa/Pb 2 0.5/0.25
Pdel 128 1.5/0.75
Prpt 64 1.0/0.5
IRT-5 Pa/Pb 16 1.5/0.75
Pdel 128 4.0/2.0
Prpt 128 4.0/2.0
Rd BLNAR TEM-1 Pdel 128 2.0/1.0
IRT-4 Pdel 256 8.0/4.0
IRT-5 Pdel 256 8.0/4.0
Table 1. Details of site-directed mutagenesis
Primersa Mutation introducedb Amino acid changec IRT type
GGTGAGCGTGGGTCTAGCGGTATCATTGCAGCACTGG C929A Arg-244!Ser IRT-2
CCCGAAGAACGTTTTCCAATGCTGAGCACTTTTAAAGTTC A407C Met-69!Leu IRT-5
GGCAACTATGGATGAACGAGATAGACAGATCGCTGAG A1022G Asn-276!Asp IRT-4d
aPrimers are listed 50 to 30 with mutation nucleotide in bold and underlined.
bNucleotides are numbered according to Sutcliffe.
cAmino acids are numbered according to Ambler.
dIRT-4 mutagenesis was performed on blaIRT-5 to give the dual mutations A407C and A1022G in blaIRT-4.
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A similar finding was observed when TEM-type extended-
spectrum b-lactamases (ESBLs) were cloned into H. influenzae,
with significantly higher MICs of cefotaxime observed when the
ESBL was expressed in a BLNAR background.13 Significantly,
the only report of a naturally occurring ESBL in Haemophilus
has been in two strains of Haemophilus parainfluenzae with
TEM-16 and altered PBPs similar to those found in BLNAR
strains of H. influenzae,14 so a background of altered PBPs in
BLNAR/BLPACR strains of H. influenzae might favour the
emergence of IRT enzymes.
It is difficult to gauge the significance of the decreased sus-
ceptibility to amoxicillin/clavulanate of the IRT-producing H.
influenzae strains in this study because the MICs cluster around
the breakpoints for amoxicillin/clavulanate used by various regu-
latory bodies. All the strains are susceptible according to CLSI
breakpoints (S  4, R  8 mg/L) but some would be considered
resistant according to either the BSAC breakpoints (S  1, R .
1 mg/L) or the recently proposed PK/PD breakpoints (S  2,
R  4 mg/L).2,15,16 The significance of the decreased suscepti-
bility might best be considered in the context of comparisons to
other naturally occurring strains. The strains produced in this
study had amoxicillin/clavulanate MICs ranging from 0.38/0.19
to 4.0/2.0 mg/L, whereas the amoxicillin/clavulanate MIC90
for 8500 strains from the Alexander study 1998–2000 was 1.0/
0.5 mg/L,17 and the MIC90 was 2.0/1.0 for 2000 b-lactamase-
positive strains surveyed by Farrell et al. in 2000–03.18 In
addition, the amoxicillin/clavulanate MICs for 108 BLNAR and
BLPACR strains characterized by Dabernat et al.6 ranged from
0.12/0.06 to 4.0/2.0 mg/L. On this basis it can be concluded
that IRT enzymes in H. influenzae could produce resistance
to amoxicillin/clavulanate significantly greater than baseline
susceptible strains, and equivalent to that shown by currently
existing BLNAR and BLPACR strains.
If IRTs in H. influenzae can produce a similar decrease in
amoxicillin/clavulanate susceptibility to that seen in naturally
occurring BLPACR and BLNAR strains, then why have IRTs
not been detected? One possible reason is that the decreased
amoxicillin/clavulanate susceptibility in BLNAR and
BLPACR strains is not actually an evolutionary response to
selective pressure of amoxicillin/clavulanate use, but rather an
incidental finding associated with the altered PBPs and
decreased cephalosporin susceptibility selected for by wide-
spread cephalosporin use. This is consistent with the obser-
vation that strains with altered PBPs are more common in
Japan where oral cephalosporin use is favoured over amoxicil-
lin and amoxicillin/clavulanate compared with the United
States and Europe.2
It is also possible that IRT-mediated decreased amoxicillin/
clavulanate susceptibility has emerged and gone undetected, par-
ticularly given that the MICs will not exceed the current CLSI
resistance breakpoint.
A lack of consensus on breakpoints and incomplete corre-
lation between phenotypic and genotypic characterization has
created difficulties and inconsistencies in detecting currently
existing BLNAR and BLPACR strains.2 In this context, detect-
ing the possible emergence of IRT-producing strains might also
be difficult. A clinical isolate that is b-lactamase-positive with
reduced amoxicillin/clavulanate susceptibility or resistance is
most probably a BLPACR strain, but could be a strain producing
an IRT. The major differentiating characteristic would be that as
a result of the altered PBP3, BLPACR strains would usually also
show reduced susceptibility or resistance to cephalosporins
whereas IRT-producing strains in this study did not.
Confirmation of IRT production would require sequencing of the
blaTEM gene.
In conclusion, IRT enzymes in H. influenzae could cause a
significant decrease in amoxicillin/clavulanate susceptibility but
would be difficult to detect using current CLSI breakpoints.
Laboratories should consider the presence of an IRT in
b-lactamase-positive strains of H. influenzae with decreased sus-
ceptibility to amoxicillin/clavulanate without a concomitant
decrease in cephalosporin susceptibility.
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